Last reviewed · How we verify
ClearCare
ClearCare is a small molecule that targets the SGLT2 receptor.
ClearCare is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | ClearCare |
|---|---|
| Sponsor | University of Waterloo |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, ClearCare reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study (NA)
- BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens (NA)
- A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand (NA)
- Fitting Children With Contact Lenses (NA)
- Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers (NA)
- Ocular Comfort and the "Aging" Lens (ERBIUM) (NA)
- Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |